In the recent APOLLO evaluation project conducted at the PATH laboratory in Seattle, Pluslife Mini Dock has gained satisfactory results in terms of test performance and usability, confirming its testing accuracy and strong usability in LMICs (Low- and Middle-Income Countries).

Funded by Bill & Melinda Gates Foundation, PATH is a nonprofit health organization that aims to advance health equity through innovation and partnerships. As the next-generation molecular platforms contribute significantly to the COVID-19 pandemic control, the PATH APOLLO (Accelerating Point-of-care mOLecuLar diagnOstics) project is designated to evaluate the performances of these innovative platforms and their potential to identify different diseases in LMICs.   

The PATH APOLLO analytical evaluation included three different panel types for assessment, namely, a ribonucleic acid panel, a viral panel, and a swab-based viral panel with a prolonged elution step. The Pluslife Mini Dock Molecular POCT System exhibited a limit of detection (LoD) comparable to 400 copies per mL. This exceptional sensitivity enables the diagnosis of pathogens at very low levels of viral load.

The usability evaluation was rated by both professional and non-professional users based on three factors: efficiency, effectiveness, and user satisfaction. The simple 3-step operation of Pluslife Mini Dock and the fast turnaround time were well reflected in the results with all users completing the workflow successfully. As a result of these simple and effective features of Pluslife Mini Dock, molecular diagnostics in LMICs could rapidly decentralized and industrialized.

Pluslife is encouraged by the positive result of the APOLLO evaluation project conducted by PATH. Pluslife will continue to work closely with healthcare organizations and constantly contribute to the advancement of global healthcare equality.